

Davide Massimi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2838714/publications.pdf>

Version: 2024-02-01

11
papers

179
citations

1307594

7
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

246
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. <i>Gastroenterology</i> , 2021, 161, 1865-1877.	1.3	46
2	A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach. <i>Gut Microbes</i> , 2022, 14, 2028366.	9.8	26
3	Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator. <i>Scientific Reports</i> , 2021, 11, 10368.	3.3	21
4	Medical and gastroenterological education during the COVID-19 outbreak. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 447-449.	17.8	18
5	Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00177.	2.5	14
6	Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation. <i>Intestinal Research</i> , 2022, 20, 114-123.	2.6	12
7	Real-Life Comparison of Different Anti-TNF Biologic Therapies for Ulcerative Colitis Treatment: A Retrospective Cohort Study. <i>Digestive Diseases</i> , 2021, 39, 16-24.	1.9	12
8	A propensity score-weighted comparison between adalimumab originator and its biosimilars, ABP501 and SB5, in inflammatory bowel disease: a multicenter Italian study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110314.	3.2	10
9	Fecal microbiota transplantation for norovirus infection: a clinical and microbiological success. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093458.	3.2	7
10	Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110233.	3.2	7
11	Faecal microbiota transplantation in <i>Clostridioides difficile</i> infection: real-life experience from an academic Italian hospital. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093431.	3.2	6